Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

This will go down in history as an incredible year for stocks. The S&P 500 hit a new all-time high 50 times.

1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever

AbbVie Inc. has rebounded from setbacks with a strong pipeline, including the promising Parkinson's drug Tavapadon, which shows blockbuster potential. Key growth drivers like SKYRIZI and RINVOQ are boosting sales, while AbbVie maintains leadership in immunology and diversifies beyond Humira. With a 3.7% yield, steady dividend growth, and strong earnings recovery, ABBV stock offers attractive value and long-term upside potential for investors.

Betting Big On AbbVie: A Prescription For Growth And Dividends

Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline and R&D capabilities NORTH CHICAGO, Ill. , Dec. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics.

AbbVie Completes Acquisition of Aliada Therapeutics

Archer-Daniels-Midland Company

Albemarle

Amcor Plc

Air Products and Chemicals

Atmos Energy

Franklin Resources

C.H. Robinson Worldwide

Chevron

Con Ed

Federal Realty Investment Trust

Hormel Foods

Johnson & Johnson

Coca-Cola

Kenvue

Medtronic

NextEra Energy

Realty Income Corp

PepsiCo

J. M. Smucker

Stanley Black & Decker

T. Rowe Price Group

Exxon Mobil

Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends

Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's disease.

AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal

Caterpillar

CVS Health

Citizens & Northern

Deere & Company

Eaton

General Dynamics

Kinder Morgan

Norfolk Southern

Orrstown Financial

Provident Financial Services

Procter & Gamble

Reynolds Consumer Products

Starbucks

AT&T

Verizon

Investing in dividend stocks allows you to earn dividend income, the best passive income stream. The power of compounding and dividend reinvestment is a wonderful component to the portfolio. All of the investing from last year and moves this year show that my aim to save 60% of my income, and making every dollar count has provided the dividend growth.

Dividend Income Summary: Lanny's November 2024 Summary

Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill. , Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult patients with diffuse large B-cell lymphoma (DLBCL) at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH).

Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma

AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson's disease on Monday and said it's on track to seek approval for the drug from the Food and Drug Administration in 2025.

AbbVie's third successful Parkinson's trial sets the stage for an eventful 2025

Time in the market generally beats timing the market. This can be enhanced by buying low and selling high. Here's how. Being an active investor, I believe that timing individual equities can complement the strategy of staying consistently invested. You're timing stocks, while staying in the market. The Dividend Train concept emphasizes the importance of timing when buying dividend stocks to maximize income and compound growth.

Don't Miss The Dividend Train: 2 Top Buys To End 2024

AbbVie said on Monday its experimental drug to treat Parkinson's disease met the main goal in a late-stage study.

AbbVie's Parkinson's disease drug meets main goal in late-stage study

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III combined score at week 261 Trial also met its key secondary endpoint, demonstrating statistically significant improvement from baseline in the MDS-UPDRS Part II score at week 261 Positive results across all three Phase 3 TEMPO trials demonstrate the potential of tavapadon as a first-in-class D1/D5 partial agonist in Parkinson's disease AbbVie is on track to submit an NDA for tavapadon to the FDA in 2025 NORTH CHICAGO, Ill. , Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease.

AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease

-New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis and treatment journeys -CLL is one of the most common leukemias among adults affecting more than 200,000 people in the U.S.1,2 NORTH CHICAGO, Ill. , Dec. 8, 2024 /PRNewswire/ -- AbbVie announced groundbreaking results today from its latest Emotional Impact Report (EIR) , a patient survey that provides an understanding of the mental health impacts of a chronic lymphocytic leukemia (CLL) diagnosis.

AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients

Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill. , Dec. 7, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, plus lenalidomide + rituximab (R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL).

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

AbbVie Inc. (NYSE:ABBV ) Citi's 2024 Global Healthcare Conference Call December 3, 2024 10:15 AM ET Company Participants Jeffrey Stewart - Executive Vice President and Chief Commercial Officer Roopal Thakkar - Executive Vice President, R&D and Chief Scientific Officer Scott Reents - Executive Vice President and Chief Financial Officer Conference Call Participants Geoff Meacham - Citigroup Geoff Meacham Morning sessions. I'm Geoff Meacham.

AbbVie Inc. (ABBV) Citi's 2024 Global Healthcare Conference (Transcript)

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

Bristol-Myers

Patterson Companies

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields

Brookfield Infrastructure Partners L.P.

Brookfield Infrastructure

Royalty Pharma

It's been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the benchmark S&P 500 (^GSPC 0.24%) index rose a whopping 57.1% higher.

3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer

Pfizer

You don't have to be an income investor to like dividends. Many billionaires who definitely don't need income still have dividend stocks in their portfolios.

3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?

Why Is AbbVie (ABBV) Down 10.2% Since Last Earnings Report?

Apple

Amazon

American Express

Alphabet

Home Depot

JPMorgan Chase & Co

NVIDIA

Invesco QQQ

Schwab US Dividend Equity ETF

Vanguard High Dividend Yield ETF

Big Tech dominates markets but faces risks like slowing growth, AI dependency, and inflated valuations. Dividend stalwarts offer a safer, smarter alternative. Dividend stocks, like those in VYM and SCHD ETFs, have matched or beat tech returns since 2021, fueled by strong cash flow, low risks, and reliable growth. By focusing on dividend stalwarts, investors can achieve long-term growth, income, and stability—outperforming tech-heavy portfolios over time.

Forget Big Tech - I'll Take Dividend Stalwarts Any Day

News for AbbVie Stock (ABBV)